image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 21.89
-3.47 %
$ 1.04 B
Market Cap
-84.6
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BLFS stock under the worst case scenario is HIDDEN Compared to the current market price of 21.9 USD, BioLife Solutions, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BLFS stock under the base case scenario is HIDDEN Compared to the current market price of 21.9 USD, BioLife Solutions, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BLFS stock under the best case scenario is HIDDEN Compared to the current market price of 21.9 USD, BioLife Solutions, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BLFS

image
$29.0$29.0$28.0$28.0$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
82.3 M REVENUE
-42.59%
-7.13 M OPERATING INCOME
89.93%
-20.2 M NET INCOME
69.61%
8.43 M OPERATING CASH FLOW
167.46%
58.3 M INVESTING CASH FLOW
226.85%
-6.78 M FINANCING CASH FLOW
-64.04%
-3.42 M REVENUE
-11.20%
1.39 M OPERATING INCOME
188.90%
12.5 M NET INCOME
181.56%
1.64 M OPERATING CASH FLOW
-65.74%
73.6 M INVESTING CASH FLOW
4480.55%
-4.09 M FINANCING CASH FLOW
-292.51%
Balance Sheet BioLife Solutions, Inc.
image
Current Assets 149 M
Cash & Short-Term Investments 105 M
Receivables 9.17 M
Other Current Assets 35 M
Non-Current Assets 251 M
Long-Term Investments 995 K
PP&E 16.8 M
Other Non-Current Assets 233 M
26.18 %8.76 %4.19 %58.32 %Total Assets$399.5m
Current Liabilities 32.7 M
Accounts Payable 3.57 M
Short-Term Debt 12.5 M
Other Current Liabilities 16.7 M
Non-Current Liabilities 17.8 M
Long-Term Debt 12.7 M
Other Non-Current Liabilities 5.12 M
7.06 %24.62 %33.03 %25.16 %10.12 %Total Liabilities$50.6m
EFFICIENCY
Earnings Waterfall BioLife Solutions, Inc.
image
Revenue 82.3 M
Cost Of Revenue 24.5 M
Gross Profit 57.8 M
Operating Expenses 64.9 M
Operating Income -7.13 M
Other Expenses 13.1 M
Net Income -20.2 M
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)82m(25m)58m(65m)(7m)(13m)(20m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.21% GROSS MARGIN
70.21%
-8.67% OPERATING MARGIN
-8.67%
-24.54% NET MARGIN
-24.54%
-5.78% ROE
-5.78%
-5.05% ROA
-5.05%
-1.87% ROIC
-1.87%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis BioLife Solutions, Inc.
image
10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -20.2 M
Depreciation & Amortization 8.66 M
Capital Expenditures -3.23 M
Stock-Based Compensation 30.9 M
Change in Working Capital 0
Others -10.9 M
Free Cash Flow 5.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets BioLife Solutions, Inc.
image
Wall Street analysts predict an average 1-year price target for BLFS of $30 , with forecasts ranging from a low of $30 to a high of $30 .
BLFS Lowest Price Target Wall Street Target
30 USD 37.05%
BLFS Average Price Target Wall Street Target
30 USD 37.05%
BLFS Highest Price Target Wall Street Target
30 USD 37.05%
Price
Max Price Target
Min Price Target
Average Price Target
30302828262624242222202018181616Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership BioLife Solutions, Inc.
image
Sold
0-3 MONTHS
2.31 M USD 7
3-6 MONTHS
2.72 M USD 6
6-9 MONTHS
1.09 M USD 6
9-12 MONTHS
594 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash. , April 7, 2025 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. prnewswire.com - 3 weeks ago
BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has consistently exceeded earnings expectations, indicating strong future potential and investor confidence. BioLife's unique focus on cell preservation and storage positions it advantageously within the CGT sector, with expected revenue growth heavily outpacing peers. seekingalpha.com - 3 weeks ago
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being. zacks.com - 1 month ago
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. prnewswire.com - 1 month ago
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW. zacks.com - 1 month ago
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.30 per share a year ago. zacks.com - 2 months ago
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results Cell Processing revenue up 7%  sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12%  over prior year to $73.5 million GAAP gross margin of 60%  and non-GAAP adjusted gross margin of 63%  for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18%  of total revenue for the fourth quarter Expects 2025  Cell Processing revenue of $86.5 to $89.0 million, up 18%  to 21%  over 2024 and total revenue of $95.5 to $99.0 million, up 16%  to 20%  over 2024 Conference call begins at 8:00 a.m. Eastern time today  BOTHELL, Wash. prnewswire.com - 2 months ago
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. prnewswire.com - 2 months ago
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com - 2 months ago
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue? BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 3 months ago
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year? Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year. zacks.com - 3 months ago
BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, BioLife Solutions (BLFS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com - 3 months ago
8. Profile Summary

BioLife Solutions, Inc. BLFS

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.04 B
Dividend Yield 0.00%
Description BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Contact 3303 Monte Villa Parkway, Bothell, WA, 98021 https://www.biolifesolutions.com
IPO Date Nov. 22, 1989
Employees 159
Officers Ms. Sarah Aebersold J.D. Chief Human Resources Officer Ms. Karen Foster Chief Quality & Operations Officer Mr. Troy Wichterman CPA Chief Financial Officer Dr. Aby J. Mathew Ph.D. Chairman of Scientific Advisory Board, Executive Vice President & Chief Scientific Officer Mr. Todd Berard Chief Commercial Officer Mr. Sean Werner Ph.D. Chief Technology Officer Mr. Roderick de Greef Chief Executive Officer & Chairman